Citius Pharmaceuticals Faces Delisting Notice
Ticker: CTXR · Form: 8-K · Filed: May 30, 2025 · CIK: 1506251
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: CTRS
TL;DR
CTRS got a delisting warning, might be in trouble with the exchange.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on May 29, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated in Nevada, is based in Cranford, NJ.
Why It Matters
This filing indicates potential issues with Citius Pharmaceuticals' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- May 29, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Cranford, NJ (location) — Principal executive offices
FAQ
What specific listing rule or standard has Citius Pharmaceuticals failed to satisfy?
The filing does not specify the exact rule or standard that Citius Pharmaceuticals has failed to satisfy, only that a notice has been received.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 29, 2025.
In which state is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the principal executive office address for Citius Pharmaceuticals, Inc.?
The principal executive office is located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What is the SEC file number for Citius Pharmaceuticals, Inc.?
The SEC file number for Citius Pharmaceuticals, Inc. is 001-38174.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding Citius Pharmaceuticals, Inc. (CTXR).